Enzo Announces Issuance of U.S. Patent for Methods of Producing Monoclonal Antibodies Against Osteoporosis Drug Target Sclero...
May 12 2020 - 8:00AM
Enzo Biochem, Inc. (NYSE: ENZ) a leading biosciences and
diagnostics company, today announced the recent issuance of U.S.
Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies,
Epitopes and Methods for Identification and Use Therefor. The
patent is directed to methods for producing monoclonal antibodies
against specific regions of human Sclerostin, a protein that is a
negative regulator of bone growth. Inhibition of Sclerostin
using monoclonal antibodies can be used to promote bone growth for
the treatment of osteoporosis.
U.S. Patent No. 10,626,170 is a member of a broader U.S. and
international patent family that includes issued patents and
pending patent applications directed to antibodies and their use in
inhibiting Sclerostin as well as small synthetic peptides and their
use in inhibiting Sclerostin in the treatment of bone disorders
such as osteoporosis.
Elazar Rabbani, Ph.D., CEO of Enzo commented: “Osteoporosis is a
prevalent disease affecting millions of Americans. This patent is
the latest to arise from Enzo’s work demonstrating a critical
regulatory role for two sulfation sites that are present in the
human Sclerostin protein. To our knowledge, this new class of
antibodies could provide an alternative to other therapeutic
antibodies used by competitors. Significantly, we have also
shown that synthetic peptides having sequences derived from these
regions can, themselves, inhibit the interaction between Sclerostin
and its receptor and, thus, could potentially also be used as
therapeutics.”
According to the National Osteoporosis Foundation (NOF),
approximately 54 million Americans have osteoporosis and low bone
mass, placing them at increased risk for osteoporosis.
Further, according to the NOF, studies suggest that approximately
one in two women and up to one in four men age 50 and older will
break a bone due to osteoporosis.
About Enzo Biochem Enzo
Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Forward-Looking Statements
Except for historical information, the matters
discussed in this release may be considered "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its
management, including those related to cash flow, gross margins,
revenues, and expenses which are dependent on a number of factors
outside of the control of the Company including, inter alia, the
markets for the Company’s products and services, costs of goods and
services, other expenses, government regulations, litigation, and
general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2019. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The
Company disclaims any obligations to update any forward-looking
statement as a result of developments occurring after the date of
this release.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO 212-583-0100 dbench@enzo.com
Investors/Media:
Melanie SolomonThe Blueshirt
Group415-217-4964melanie@blueshirtgroup.com
Steve AnrederAnreder &
Company212-532-3232Steven.anreder@anreder.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024